Indeed, TP53 mutations are far more frequent in secondary AML, including 15–25% of AML transformed from antecedent MDS or other myeloproliferative neoplasia (MPN) and 20–35% of therapy-related AML following exposure to cytotoxic chemotherapy or radiation [5,53,54]. Here, TP53 is linked to myelodysplastic syndrome.